About NuCana (NASDAQ:NCNA)
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
NuCana (NASDAQ:NCNA) Frequently Asked Questions
What is NuCana's stock symbol?
NuCana trades on the NASDAQ under the ticker symbol "NCNA."
Where is NuCana's stock going? Where will NuCana's stock price be in 2018?
4 brokers have issued twelve-month price objectives for NuCana's stock. Their predictions range from $23.00 to $25.00. On average, they anticipate NuCana's stock price to reach $24.00 in the next twelve months. View Analyst Ratings for NuCana.
Who are some of NuCana's key competitors?
Some companies that are related to NuCana include ARMO Biosciences (ARMO), Acorda Therapeutics (ACOR), Genomic Health (GHDX), Wave Life Sciences (WVE), G1 Therapeutics (GTHX), Myovant Sciences (MYOV), Revance Therapeutics (RVNC), TherapeuticsMD (TXMD), Bavarian Nordic (BVNRY), DBV Technologies (DBVT), Audentes Therapeutics (BOLD), Athenex (ATNX), Intellia Therapeutics (NTLA), Zai Lab (ZLAB), Adaptimmune Therapeutics (ADAP), Dynavax Technologies (DVAX), Retrophin (RTRX) and Amarin (AMRN).
Who are NuCana's key executives?
NuCana's management team includes the folowing people:
- Christopher B. Wood M.D., Chairman of the Board, Co-Founder & Chief Medical Officer (Age 70)
- Hugh S. Griffith, Chief Executive Officer, Founder, Director (Age 48)
- Donald Munoz, Chief Financial Officer
- Martin Mellish, Non-Executive Director
- Rafaele Tordjman, Non-Executive Director
When did NuCana IPO?
(NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.
When does NuCana's lock-up period expire?
NuCana's lock-up period expires on Tuesday, March 27th. NuCana had issued 6,667,000 shares in its public offering on September 28th. The total size of the offering was $100,005,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
Who owns NuCana stock?
NuCana's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sofinnova Management VIII L.L.C. (14.67%), Alliancebernstein L.P. (2.86%), UBS Asset Management Americas Inc. (1.46%), Alps Advisors Inc. (0.11%), Millennium Management LLC (0.10%) and Citadel Advisors LLC (0.07%). View Institutional Ownership Trends for NuCana.
Who sold NuCana stock? Who is selling NuCana stock?
Who bought NuCana stock? Who is buying NuCana stock?
NuCana's stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Management VIII L.L.C., Alliancebernstein L.P., Alps Advisors Inc. and UBS Asset Management Americas Inc.. View Insider Buying and Selling for NuCana.
How do I buy NuCana stock?
Shares of NuCana can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuCana's stock price today?
One share of NuCana stock can currently be purchased for approximately $18.74.
How big of a company is NuCana?
NuCana has a market capitalization of $596.14 million. NuCana employs 16 workers across the globe.
How can I contact NuCana?
NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-0-13-1248-3660.
MarketBeat Community Rating for NuCana (NCNA)MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for NuCana (NASDAQ:NCNA)
No earnings announcements for this company have been tracked by MarketBeat.com
NuCana (NASDAQ:NCNA) Earnings Estimates
2018 EPS Consensus Estimate: ($0.86)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for NuCana (NASDAQ:NCNA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for NuCana (NASDAQ NCNA)
No insider trades for this company have been tracked by MarketBeat.com
NuCana (NASDAQ NCNA) News Headlines
NuCana (NASDAQ:NCNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NuCana (NASDAQ:NCNA) Income Statement, Balance Sheet and Cash Flow Statement
NuCana (NASDAQ NCNA) Stock Chart for Sunday, March, 18, 2018